SRZN
Surrozen, Inc.
NASDAQ · USHealthcareBiotechnology
$22.16+0.91%
Price as of Jul 20, 2026
SRZN profitability
Surrozen, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 99.1%
- EBITDA margin
- -4567.0%
- EBIT margin
- -573.8%
- Net margin
- -4571.1%
- Free cash flow margin
- -449.4%
Returns
- Return on equity
- 123.2%
- Return on assets
- -283.8%
- Return on invested capital
- 15.8%
- Asset turnover
- 0.07x
Cash efficiency
- Cash from operations
- -$33.5M
- Cash per share
- $9.21
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.